Literature DB >> 33760971

Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions.

Hayley F North1,2, Jason Bruggemann1,2, Vanessa Cropley3, Vaidy Swaminathan4,5, Suresh Sundram4,5,6,7, Rhoshel Lenroot1,2,8, Avril M Pereira3,7, Andrew Zalesky3, Chad Bousman3,9, Christos Pantelis3, Thomas W Weickert1,2,10, Cynthia Shannon Weickert11,12,13.   

Abstract

While the biological substrates of brain and behavioural changes in persons with schizophrenia remain unclear, increasing evidence implicates that inflammation is involved. In schizophrenia, including first-episode psychosis and anti-psychotic naïve patients, there are numerous reports of increased peripheral inflammation, cognitive deficits and neuropathologies such as cortical thinning. Research defining the relationship between inflammation and schizophrenia symptomatology and neuropathology is needed. Therefore, we analysed the level of C-reactive protein (CRP), a peripheral inflammation marker, and its relationship with cognitive functioning in a cohort of 644 controls and 499 schizophrenia patients. In a subset of individuals who underwent MRI scanning (99 controls and 194 schizophrenia cases), we tested if serum CRP was associated with cortical thickness. CRP was significantly increased in schizophrenia patients compared to controls, co-varying for age, sex, overweight/obesity and diabetes (p < 0.006E-10). In schizophrenia, increased CRP was mildly associated with worse performance in attention, controlling for age, sex and education (R =- 0.15, p = 0.001). Further, increased CRP was associated with reduced cortical thickness in three regions related to attention: the caudal middle frontal, the pars opercularis and the posterior cingulate cortices, which remained significant after controlling for multiple comparisons (all p < 0.05). Together, these findings indicate that increased peripheral inflammation is associated with deficits in cognitive function and brain structure in schizophrenia, especially reduced attention and reduced cortical thickness in associated brain regions. Using CRP as a biomarker of peripheral inflammation in persons with schizophrenia may help to identify vulnerable patients and those that may benefit from adjunctive anti-inflammatory treatments.

Entities:  

Keywords:  Biomarker; CRP; Immune system; MRI; Neuropathology; RBANS

Mesh:

Substances:

Year:  2021        PMID: 33760971     DOI: 10.1007/s00406-021-01237-z

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  74 in total

Review 1.  Blood-brain barrier transport of cytokines: a mechanism for neuropathology.

Authors:  William A Banks
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

Review 2.  The blood-brain barrier in psychosis.

Authors:  Thomas A Pollak; Svetlana Drndarski; James M Stone; Anthony S David; Philip McGuire; N Joan Abbott
Journal:  Lancet Psychiatry       Date:  2017-08-03       Impact factor: 27.083

Review 3.  Maternal immune activation and abnormal brain development across CNS disorders.

Authors:  Irene Knuesel; Laurie Chicha; Markus Britschgi; Scott A Schobel; Michael Bodmer; Jessica A Hellings; Stephen Toovey; Eric P Prinssen
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

4.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

5.  C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications.

Authors:  B S Fernandes; J Steiner; H-G Bernstein; S Dodd; J A Pasco; O M Dean; P Nardin; C-A Gonçalves; M Berk
Journal:  Mol Psychiatry       Date:  2015-07-14       Impact factor: 15.992

Review 6.  Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review.

Authors:  Błażej Misiak; Bartłomiej Stańczykiewicz; Kamila Kotowicz; Janusz K Rybakowski; Jerzy Samochowiec; Dorota Frydecka
Journal:  Schizophr Res       Date:  2017-04-14       Impact factor: 4.939

Review 7.  Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier.

Authors:  Jonathan I Spencer; Jack S Bell; Gabriele C DeLuca
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-08-31       Impact factor: 10.154

Review 8.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.

Authors:  Golam M Khandaker; Lesley Cousins; Julia Deakin; Belinda R Lennox; Robert Yolken; Peter B Jones
Journal:  Lancet Psychiatry       Date:  2015-02-25       Impact factor: 27.083

9.  C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review.

Authors:  Guillaume Fond; Christophe Lançon; Pascal Auquier; Laurent Boyer
Journal:  Front Psychiatry       Date:  2018-08-23       Impact factor: 4.157

Review 10.  CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?

Authors:  Brendon J Coventry; Martin L Ashdown; Michael A Quinn; Svetomir N Markovic; Steven L Yatomi-Clarke; Andrew P Robinson
Journal:  J Transl Med       Date:  2009-11-30       Impact factor: 5.531

View more
  8 in total

1.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.

Authors:  M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

2.  A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia.

Authors:  Egor Chumakov; Mariia Dorofeikova; Kristina Tsyrenova; Nataliia Petrova
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435

3.  Recommendations of the Schizophrenia Expert Center network for adequate physical activity in real-world schizophrenia (FACE-SZ).

Authors:  Pierre-Louis Sunhary De Verville; Brendon Stubbs; Damien Etchecopar-Etchart; Ophélia Godin; Christelle Andrieu-Haller; Fabrice Berna; Bruno Aouizerate; Delphine Capdevielle; Isabelle Chereau; Julie Clauss-Kobayashi; Nathalie Coulon; Jean-Michel Dorey; Caroline Dubertret; Sylvain Leignier; Jasmina Mallet; David Misdrahi; Catherine Passerieux; Baptiste Pignon; Romain Rey; Mathieu Urbach; Pierre-Michel Llorca; Franck Schürhoff; Christophe Lançon; Laurent Boyer; Guillaume Fond
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-04-20       Impact factor: 5.760

4.  The Interplay between Vitamin D, Exposure of Anticholinergic Antipsychotics and Cognition in Schizophrenia.

Authors:  Arnim Johannes Gaebler; Michelle Finner-Prével; Federico Pacheco Sudar; Felizia Hannah Langer; Fatih Keskin; Annika Gebel; Jana Zweerings; Klaus Mathiak
Journal:  Biomedicines       Date:  2022-05-09

5.  A schizophrenia subgroup with elevated inflammation displays reduced microglia, increased peripheral immune cell and altered neurogenesis marker gene expression in the subependymal zone.

Authors:  Hayley F North; Christin Weissleder; Janice M Fullerton; Rachel Sager; Maree J Webster; Cynthia Shannon Weickert
Journal:  Transl Psychiatry       Date:  2021-12-15       Impact factor: 6.222

6.  Elevated Serum Purine Levels in Schizophrenia: A Reverse Translational Study to Identify Novel Inflammatory Biomarkers.

Authors:  Zsüliet Kristóf; Mária Baranyi; Pál Tod; Paula Mut-Arbona; Kornél Demeter; István Bitter; Beáta Sperlágh
Journal:  Int J Neuropsychopharmacol       Date:  2022-08-16       Impact factor: 5.678

7.  Peripheral inflammation levels associated with degree of advanced brain aging in schizophrenia.

Authors:  Federica Klaus; Tanya T Nguyen; Michael L Thomas; Sharon C Liou; Benchawanna Soontornniyomkij; Kyle Mitchell; Rebecca Daly; Ashley N Sutherland; Dilip V Jeste; Lisa T Eyler
Journal:  Front Psychiatry       Date:  2022-08-12       Impact factor: 5.435

8.  NLRP3 Influences Cognitive Function in Schizophrenia in Han Chinese.

Authors:  Ruimei Liu; Wei Tang; Weiping Wang; Feikang Xu; Weixing Fan; Yi Zhang; Chen Zhang
Journal:  Front Genet       Date:  2021-12-10       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.